Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects

被引:49
|
作者
Zuenkler, Bemd J. [1 ]
机构
[1] Fed Inst Drugs & Med Devices, D-53175 Bonn, Germany
关键词
cardiotoxicity; Torsades de pointes arrhythmia; HERG channel; ATP-sensitive K+ channel; pancreatic beta-cell; sulfonylureas;
D O I
10.1016/j.pharmthera.2006.03.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Torsades de pointes (TdP) arrhythmia is a potentially fatal form of ventricular arrhythmia that occurs under conditions where cardiac repolarization is delayed (as indicated by prolonged QT intervals from electrocardiographic recordings). A likely mechanism for QT interval prolongation and UP arrhythmias is blockade of the rapid component of the cardiac delayed rectifier K+ current (I-Kr), which is encoded by human ether-a-go-go-related gene (HERG). Over 100 non-cardiovascular drugs have the potential to induce QT interval prolongations in the electrocardiogram (ECG) or TdP arrhythmias. The binding site of most HERG channel blockers is located inside the central cavity of the channel. An evaluation of possible effects on HERG channels during the development of novel drugs is recommended by international guidelines. During cardiac ischaemia activation of ATP-sensitive K+ (K-ATP) channels contributes to action potential (AP) shortening which is either cardiotoxic by inducing re-entrant ventricular arrhythmias or cardioprotective by inducing energy-sparing effects or ischaemic preconditioning (IPC). K-ATP channels are formed by an inward-rectifier K+ channel (Kir6.0) and a sulfonylurea receptor (SUR) subunit: Kir6.2 and SUR2A in cardiac myocytes, Kir6.2 and SUR1 in pancreatic beta-cells. Sulfonylureas and glinides stimulate insulin secretion via blockade of the pancreatic P-cell K-ATP channel. Clinical studies about cardiotoxic effects of sulfonylureas are contradictory.. Sulfonylureas and glinides differ in their selectivity for pancreatic over cardiovascular K-ATP channels, being either selective (tolbutamide, glibenclamide) or non-selective (repaglinide). The possibility exists that non-selective K-ATP channel inhibitors might have cardiovascular side effects. Blockers of the pore-forming Kir6.2 subunit are insulin secretagogues and might have cardioprotective or cardiotoxic effects during cardiac ischaemia. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 37
页数:26
相关论文
共 50 条
  • [1] The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels
    Thomas, D
    Gut, B
    Wendt-Nordahl, G
    Kiehn, J
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02): : 543 - 548
  • [2] Effect of β-adrenoceptor blockers on Human Ether-a-go-go-Related gene (HERG) potassium channels
    Dupuis, DS
    Klaerke, DA
    Olesen, SP
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (02) : 123 - 130
  • [3] Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels
    Limberis, James T.
    Su, Zhi
    Cox, Bryan F.
    Gintant, Gary A.
    Martin, Ruth L.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) : 1059 - 1065
  • [4] Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel
    Walker, BD
    Singleton, CB
    Tie, H
    Bursill, JA
    Wyse, KR
    Valenzuela, SM
    Breit, SN
    Campbell, TJ
    CARDIOVASCULAR RESEARCH, 2000, 48 (01) : 44 - 58
  • [5] Propranolol inhibits the human ether-a-go-go-related gene potassium channels
    Yao, XZ
    McIntyre, MS
    Lang, DG
    Song, IH
    Becherer, JD
    Hashim, MA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 519 (03) : 208 - 211
  • [6] Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related gene (HERG) channels
    Dong, DL
    Li, Z
    Wang, HZ
    Du, ZM
    Song, WH
    Yang, BF
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (05) : 209 - 212
  • [7] Mallotoxin is a novel human Ether-a-go-go-related gene (hERG) potassium channel activator
    Zeng, Haoyu
    Lozinskaya, Irina M.
    Lin, Zuojun
    Willette, Robert N.
    Brooks, David P.
    Xu, Xiaoping
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (02): : 957 - 962
  • [8] Interactions at Human ether-a-go-go-Related Gene Channels
    Friemel, Anne
    Zuenkler, Bernd J.
    TOXICOLOGICAL SCIENCES, 2010, 114 (02) : 346 - 355
  • [9] Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma
    Shugg, Tyler
    Dave, Nimita
    Amarh, Enoch
    Assiri, Abdullah A.
    Pollok, Karen E.
    Overholser, Brian R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (03) : 357 - 365
  • [10] Direct block of human ether-a-go-go-related gene potassium channels by caffeine
    Cockerill, SL
    Mitcheson, JS
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02): : 860 - 868